Lane Simonian article:
This article could have been written a year ago, or more. Response:
1. Of course protein kinase C is not inhibited "enough to alter the course of the disease." No one, including Anavex, has suggested 2-73 will indefinitely inhibit protein kinase C.
2. Let's get real and drop the hyperbole: 2-73 most likely will not cure or indefinitely alleviate the eventual progression of AD. None of us honestly believes this or has gone out of their way to strongly suggest such a result for the drug.
3. We know virtually every AD drug fails eventually and our hope is very well grounded in the expectation that 2-73 will significantly improve SOC enough to get FDA backing.
4. We also know enough as investors to shore up profits at the opportune time; some before FDA window, of course. Who holds on to what portion of their investment through the finish line is up to each individual.
On balance, nothing has changed: the weak bail and the committed hold strong. Much too early to get jittery. There will be plenty of time for that as we progress through the trials. I'm well situated with a long position and will remain so. Have a few options I may cut loose when timing appropriate; otherwise, coasting like everybody else who understands how these in segments work.
All the best.
Market Data 
Markets 
